Taken together, our results support that determination of PTPRG expression level by flow cytometry as a new biomarker of response to treatment with BCR-ABL1 TKIs is a useful tool for studying its role in tumor progression and predicting the response to therapeutic interventions and clinical management in patients with CML. This evidence concerns the gene ABL1 and neoplasm.